StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.27−0.01 (-3.26%)

Close on Nov 18, 2026Market cap $51.83MP/E –Yield –

Heron Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Heron Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$11.61M. For fiscal 2025 it was -$27.59M. The highest annual figure on record is -$5.48M in fiscal 2010.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$27.59M–
FY2024Dec 31, 2024-$22.53M–
FY2023Dec 31, 2023-$58.79M–
FY2022Dec 31, 2022-$146.91M–
FY2021Dec 31, 2021-$203.35M–
FY2020Dec 31, 2020-$184.82M–
FY2019Dec 31, 2019-$124.58M–
FY2018Dec 31, 2018-$191.81M–
FY2017Dec 31, 2017-$170.30M–
FY2016Dec 31, 2016-$134.10M–
FY2015Dec 31, 2015-$78.53M–
FY2014Dec 31, 2014-$60.28M–
FY2013Dec 31, 2013-$40.76M–
FY2012Dec 31, 2012-$17.01M–
FY2011Dec 31, 2011-$7.72M–
FY2010Dec 31, 2010-$5.48M–
FY2009Dec 31, 2009-$11.00M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.21M–
Q1 FY2026Mar 31, 2026-$1.54M–
Q4 FY2025Dec 31, 2025-$9.18M–
Q3 FY2025Sep 30, 2025$1.33M-60.5%
Q2 FY2025Jun 30, 2025-$10.87M–
Q1 FY2025Mar 31, 2025-$8.87M–
Q4 FY2024Dec 31, 2024-$11.78M-579.8%
Q3 FY2024Sep 30, 2024$3.37M–
Q2 FY2024Jun 30, 2024-$4.60M–
Q1 FY2024Mar 31, 2024-$9.52M–
Q4 FY2023Dec 31, 2023$2.46M–
Q3 FY2023Sep 30, 2023-$9.18M–
Q2 FY2023Jun 30, 2023-$27.17M–
Q1 FY2023Mar 31, 2023-$24.90M–
Q4 FY2022Dec 31, 2022-$37.53M–
Q3 FY2022Sep 30, 2022-$37.07M–
Q2 FY2022Jun 30, 2022-$28.37M–
Q1 FY2022Mar 31, 2022-$43.94M–
Q4 FY2021Dec 31, 2021-$45.26M–
Q3 FY2021Sep 30, 2021-$53.17M–
Q2 FY2021Jun 30, 2021-$62.99M–
Q1 FY2021Mar 31, 2021-$41.94M–
Q4 FY2020Dec 31, 2020-$52.55M–
Q3 FY2020Sep 30, 2020-$42.05M–
Q2 FY2020Jun 30, 2020-$57.28M–
Q1 FY2020Mar 31, 2020-$32.94M–
Q4 FY2019Dec 31, 2019-$26.98M–
Q3 FY2019Sep 30, 2019-$25.47M–
Q2 FY2019Jun 30, 2019-$23.11M–
Q1 FY2019Mar 31, 2019-$49.02M–
Q4 FY2018Dec 31, 2018-$33.49M–
Q3 FY2018Sep 30, 2018-$35.88M–
Q2 FY2018Jun 30, 2018-$60.73M–
Q1 FY2018Mar 31, 2018-$61.71M–
Q4 FY2017Dec 31, 2017-$47.15M–
Q3 FY2017Sep 30, 2017-$40.54M–
Q2 FY2017Jun 30, 2017-$32.03M–
Q1 FY2017Mar 31, 2017-$50.58M–
Q4 FY2016Dec 31, 2016-$38.52M–
Q3 FY2016Sep 30, 2016-$36.12M–

More Heron Therapeutics figures

See a number that looks wrong?